Originality of Submission
Contributions submitted to EHP must be original works of the author(s) and must not have been previously published in print or online or simultaneously submitted to another publication. Previously published material (e.g., figures, tables) may be included with the proper attribution and permission.
The following content may be considered for publication by EHP if fully disclosed by the author(s):
- Manuscripts based on dissertations that have been published in their entirety by a university in partial fulfillment of a degree
- Manuscripts that include data presented at a scientific meeting but not published in full or under review for publication elsewhere
- Manuscripts deposited in a preprint service such as bioRxiv
It is the authors’ responsibility to make a full statement to the Editor-in-Chief concerning materials in a manuscript that might be considered redundant or duplicative.
Dule-use research yields findings that could, based on current understanding, be used to cause harm to public health and safety. Any paper flagged by EHP editors for potential dual-use issues will undergo an additional level of review concerning the implications to society of publishing such a paper.
Authors must declare all actual or potential competing financial interests that might reasonably be perceived as relevant. Disclosure of competing financial interests does not imply that the information in the article is questionable or that conclusions are biased. Decisions to publish or reject an article will not be based solely on a declaration of a competing financial interest.
For each manuscript, authors must submit a Competing Financial Interests Declaration (CFID) form. A statement of disclosure consistent with the information contained in the CFID form must be included as its own “Competing Financial Interests” section on the title page of the submitted manuscript. Manuscripts will not be processed unless a CFID form has been submitted.
The CFID should cover all the authors. If no competing financial interests exist, the Competing Financial Interests section should include the following statement: “The authors declare they have no actual or potential competing financial interests.” If only some authors declare competing financial interests, detail those interests and then include the following statement: “The other authors declare they have no actual or potential competing financial interests.”
What qualifies as a competing financial interest? Authors must disclose all actual or potential competing financial interest occurring within the last 3 years, including but not limited to:
- Grant support
- Relevant employment (past, present, or firm offer of future)
- Patents (pending or applied)
- Payment for expert witness or testimony
- Personal financial interests by the author(s), immediate family members, or institutional affiliations that may gain or lose financially through publication of the article
- Forms of compensation, including travel funding, consultancies, board positions, patent and royalty arrangements, stock shares, or bonds
Diversified mutual funds or investment trusts do not constitute a competing financial interest. Authors should carefully examine the wording of documents such as grants and contracts to determine whether there might be an actual or potential competing financial interest.
As a condition of review and publication, authors must further certify that their freedom to design, conduct, interpret, and publish research is not compromised by any controlling sponsor.
Competing interest in peer review: Editors and reviewers are asked to disclose to the Editor-in-Chief any actual or potential competing interests, both financial and nonfinancial, that could reasonably be perceived as relevant to the manuscript under review. Competing nonfinancial interests include former or current mentor–student relationships, faculty appointments in the same department or organization, familial relationships, service on advisory boards that oversee the research under review, collaborations, or membership in organizations that hold ideological views that are contradictory to the theme or topic under review.
EHP expects that each author has made a substantial contribution to the work. All authors also must be accountable for their own contributions and must have confidence in the integrity of the contributions of their co-authors. The corresponding author must confirm that each author agrees with the author lineup, the order of the names, and the content of the manuscript.
Changes to the author lineup after submission (i.e., to add or remove an author, or to change the order of authors) require written approval from each author.
It is the corresponding author’s responsibility to coordinate co-author approvals of the original and final author lineup. Approvals on behalf of an author will not be accepted. If approval for the new lineup is not obtained from all authors, EHP will either publish the paper with the original lineup or withdraw the article at the request of the authors.
Information about data sharing protocols, options for accessing data, and links to data repositories may be provided in the “Acknowledgments” section. Authors may also provide links to data repositories in the methods or results sections of their manuscripts, as appropriate. As is standard practice, genomics data should be deposited into an acceptable repository (e.g., the National Center for Biotechnology Information).